DK3137102T3 - Apc til anvendelse til behandling af unormal kutan ardannelse - Google Patents
Apc til anvendelse til behandling af unormal kutan ardannelse Download PDFInfo
- Publication number
- DK3137102T3 DK3137102T3 DK14889425.6T DK14889425T DK3137102T3 DK 3137102 T3 DK3137102 T3 DK 3137102T3 DK 14889425 T DK14889425 T DK 14889425T DK 3137102 T3 DK3137102 T3 DK 3137102T3
- Authority
- DK
- Denmark
- Prior art keywords
- cutane
- apc
- abnormal
- formation
- treatment
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014901397A AU2014901397A0 (en) | 2014-04-16 | Treatment of abnormal cutaneous scarring | |
| PCT/AU2014/050323 WO2015157791A1 (en) | 2014-04-16 | 2014-10-29 | Treatment of abnormal cutaneous scarring |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3137102T3 true DK3137102T3 (da) | 2021-10-11 |
Family
ID=54323254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14889425.6T DK3137102T3 (da) | 2014-04-16 | 2014-10-29 | Apc til anvendelse til behandling af unormal kutan ardannelse |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170042982A1 (enExample) |
| EP (1) | EP3137102B1 (enExample) |
| JP (2) | JP2017513944A (enExample) |
| CN (1) | CN106573040B (enExample) |
| AU (1) | AU2014391082B2 (enExample) |
| CA (1) | CA2946028C (enExample) |
| DK (1) | DK3137102T3 (enExample) |
| ES (1) | ES2890675T3 (enExample) |
| PL (1) | PL3137102T3 (enExample) |
| PT (1) | PT3137102T (enExample) |
| WO (1) | WO2015157791A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104394883B (zh) * | 2012-07-04 | 2017-05-31 | 悉尼大学 | 炎性皮肤病症的治疗 |
| US20170035862A1 (en) | 2014-04-16 | 2017-02-09 | Zz Biotech Llc | Use of APC analogue for wound healing |
| CA3134041A1 (en) * | 2019-03-19 | 2020-09-24 | Figene, Llc | Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof |
| CN113073082A (zh) * | 2021-03-19 | 2021-07-06 | 广州远想生物科技有限公司 | TGF-β3间充质干细胞外泌体及其制备方法和应用 |
| CN114788711A (zh) * | 2022-04-26 | 2022-07-26 | 李娜 | 一种瘢痕评估方法及系统 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US5516650A (en) | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| US4959318A (en) | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
| EP0380508A4 (en) | 1987-05-18 | 1991-04-03 | Integrated Genetics, Inc. | Improved protein c molecules and method for making and activating same |
| US5084274A (en) | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
| US4981952A (en) | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
| US5093117A (en) | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
| AT402260B (de) | 1990-08-16 | 1997-03-25 | Immuno Ag | Protein c-hältige pharmazeutische präparation |
| US5571786A (en) | 1990-08-16 | 1996-11-05 | Immuno Aktiengesellschaft | Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation |
| AT397615B (de) | 1991-05-14 | 1994-05-25 | Immuno Ag | Arzneimittel enthaltend protein c |
| WO1993009807A1 (en) | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels |
| MY110664A (en) | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| DE4239150A1 (de) | 1992-11-20 | 1994-05-26 | Thomae Gmbh Dr K | O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
| JP3043558B2 (ja) | 1993-10-29 | 2000-05-22 | 財団法人化学及血清療法研究所 | ヒト活性化プロテインｃ調製物及びその製法 |
| AU2467395A (en) | 1994-05-04 | 1995-11-29 | Board Of Trustees Of The University Of Arkansas, The | Novel ophthalmologic uses of protein c |
| PL195642B1 (pl) | 1997-04-28 | 2007-10-31 | Lilly Co Eli | Sposób przetwarzania wodnego roztworu aktywowanego białka C |
| HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| WO2001056532A2 (en) | 2000-02-04 | 2001-08-09 | The Scripps Research Institute | Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| AU2001232799A1 (en) | 2000-02-11 | 2001-08-20 | Eli Lilly And Company | Protein c derivatives |
| ES2242740T3 (es) * | 2000-03-28 | 2005-11-16 | Eli Lilly And Company | Proteina c activada para el tratamiento de pancreatitis. |
| AU1038802A (en) * | 2000-10-18 | 2002-04-29 | Maxygen Aps | Protein c or activated protein c-like molecules |
| ES2384099T3 (es) * | 2001-06-13 | 2012-06-29 | The University Of Sydney | Proteína C para cicatrización de heridas |
| WO2004041296A2 (en) | 2002-11-06 | 2004-05-21 | Novo Nordisk A/S | Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides |
| EP1477166B1 (de) * | 2003-04-28 | 2006-08-23 | Biofrontera Bioscience GmbH | Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis |
| US9192657B2 (en) | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| WO2005007820A2 (en) * | 2003-07-08 | 2005-01-27 | The Scripps Research Institute | Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| US20070224150A1 (en) | 2005-03-24 | 2007-09-27 | Yongji Chung | Growth factor for hair and skin treatment |
| CN101262880A (zh) * | 2005-06-24 | 2008-09-10 | 德拉格雷丘尔公司 | 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物 |
| GR1005700B (el) | 2006-09-01 | 2007-10-22 | (40%) ����� �������� | Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα |
| CA2668187A1 (en) * | 2006-10-31 | 2008-06-19 | The Scripps Research Institute | Dosing regimen of activated protein c and variants having reduced anticoagulant activity |
| GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
| ES2316312B1 (es) | 2008-06-20 | 2010-02-08 | Ignacio Umbert Millet | Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas. |
| EP2157176A1 (en) | 2008-08-20 | 2010-02-24 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Protein C Variants |
| CN101912450A (zh) | 2010-09-01 | 2010-12-15 | 吴业刚 | 一种治疗脚气皮炎的中西药组合物及其制备方法 |
| CN104394883B (zh) * | 2012-07-04 | 2017-05-31 | 悉尼大学 | 炎性皮肤病症的治疗 |
| US20170035862A1 (en) | 2014-04-16 | 2017-02-09 | Zz Biotech Llc | Use of APC analogue for wound healing |
-
2014
- 2014-10-29 EP EP14889425.6A patent/EP3137102B1/en active Active
- 2014-10-29 PL PL14889425T patent/PL3137102T3/pl unknown
- 2014-10-29 AU AU2014391082A patent/AU2014391082B2/en active Active
- 2014-10-29 CA CA2946028A patent/CA2946028C/en active Active
- 2014-10-29 CN CN201480078924.1A patent/CN106573040B/zh active Active
- 2014-10-29 JP JP2017505684A patent/JP2017513944A/ja active Pending
- 2014-10-29 ES ES14889425T patent/ES2890675T3/es active Active
- 2014-10-29 US US15/304,446 patent/US20170042982A1/en not_active Abandoned
- 2014-10-29 DK DK14889425.6T patent/DK3137102T3/da active
- 2014-10-29 PT PT148894256T patent/PT3137102T/pt unknown
- 2014-10-29 WO PCT/AU2014/050323 patent/WO2015157791A1/en not_active Ceased
-
2018
- 2018-10-09 US US16/155,475 patent/US20190060421A1/en not_active Abandoned
-
2019
- 2019-09-30 JP JP2019179634A patent/JP6846063B2/ja active Active
- 2019-12-11 US US16/710,387 patent/US11491214B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190060421A1 (en) | 2019-02-28 |
| CN106573040A (zh) | 2017-04-19 |
| CN106573040B (zh) | 2021-07-06 |
| JP2017513944A (ja) | 2017-06-01 |
| EP3137102A4 (en) | 2017-12-20 |
| PL3137102T3 (pl) | 2022-02-07 |
| US20170042982A1 (en) | 2017-02-16 |
| CA2946028A1 (en) | 2015-10-22 |
| ES2890675T3 (es) | 2022-01-21 |
| EP3137102B1 (en) | 2021-07-14 |
| CA2946028C (en) | 2022-10-11 |
| JP6846063B2 (ja) | 2021-03-24 |
| EP3137102A1 (en) | 2017-03-08 |
| AU2014391082A1 (en) | 2016-11-03 |
| PT3137102T (pt) | 2021-09-28 |
| US20200108128A1 (en) | 2020-04-09 |
| WO2015157791A1 (en) | 2015-10-22 |
| JP2020023519A (ja) | 2020-02-13 |
| US11491214B2 (en) | 2022-11-08 |
| AU2014391082B2 (en) | 2020-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| IL247452A0 (en) | Compounds for treatment of complement mediated disorders | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3261640T3 (da) | 5ht-agonister til behandling af epilepsilidelser | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3119408T3 (da) | Overfladereageret calciumkarbonat til desensibilisering af tænder | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3126373T3 (da) | Fremgangsmåde til fremstilling af amg 416 | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
| DK3324824T3 (da) | Fremgangsmåde til behandling af binokulare dysfunktioner | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose |